använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Corporate Finance

Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders.

read more

About Us

Vator Securities executes on opportunities that accelerate growth for its client companies whilst delivering results to the firm’s sophisticated investor clientele.

read more

On June 9th, Vator Securities arranged a Vator Tech Days event, focusing on innovative technologies for a future society. The event was an opporunity for investors to meet some of the most exciting and fast-growing companies in that field.

The participating companies were Soltech Energy Sweden, Renewcell, Nexam Chemical, Ljusgårda, Minesto, JonDeTech, Resolution Games, Pharem Biotech, PowerCell Sweden, Swedish Stirling, OXE Marine and Sivers Semiconductors.

Watch the presentations from the event

Vator Securities advises Umecrine Cognition on 35 MSEK Private Placement

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 35,1 million.

Umecrine Cognition is developing golexanolone, a drug candidate with a completely new type of mechanism of action targeting the GABAA receptor in the brain.

read more

Vator Securities advises Plastics Unbound on 30 MSEK Private Placement

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 30,3 million.

Plastics Unbound has successfully completed technical and commercial validation through Tier-1 customer trials and production applications and is now transitioning into larger volume orders.

read more

Vator Swiss Nordic Bio 2022

VATOR SWISS NORDIC BIO 2022 – The Leading Annual European Healthcare Investor Summit in Zürich.

Vator Securities and Business Sweden & partners have the pleasure to invite you to the annual European healthcare investor conference VATOR SWISS NORDIC BIO, connecting fast growing Nordic publicly listed healthcare companies, the most exciting start-ups, and the European investor community

read more

Vator Securities advises Xintela on 28 MSEK Directed Share Issues

Vator Securities acts as Sole Bookrunner in connection with the transactions raising SEK approximately SEK 28 million.

Xintela is developing novel stem cell therapies and antibody based targeted cancer therapies using on the integrin marker technology platform XINMARK®. The patented stem cell product XSTEM®, produced in Xintela’s own GMP-facility, is entering a clinical phase I/IIa study in 2021. 

read more

More News